Business Description
Altimmune Inc
NAICS : 325412
SIC : 2834
ISIN : US02155H1014
Description
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 78.61 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 17.27 | |||||
| Beneish M-Score | -2.08 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -70.7 | |||||
| 3-Year EBITDA Growth Rate | 7.8 | |||||
| 3-Year EPS without NRI Growth Rate | 9.3 | |||||
| 3-Year FCF Growth Rate | -1.8 | |||||
| 3-Year Book Growth Rate | -23.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -9.01 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.01 | |||||
| 9-Day RSI | 36.27 | |||||
| 14-Day RSI | 43.18 | |||||
| 6-1 Month Momentum % | 22.84 | |||||
| 12-1 Month Momentum % | 9.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 16.87 | |||||
| Quick Ratio | 16.87 | |||||
| Cash Ratio | 16.14 | |||||
| Days Sales Outstanding | 4416.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -23.9 | |||||
| Shareholder Yield % | -12.89 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -191365.39 | |||||
| Net Margin % | -199076.92 | |||||
| FCF Margin % | -145844.9 | |||||
| ROE % | -64.43 | |||||
| ROA % | -58.37 | |||||
| ROIC % | -2242.02 | |||||
| ROC (Joel Greenblatt) % | -17914.5 | |||||
| ROCE % | -62.53 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 8000 | |||||
| PB Ratio | 4.27 | |||||
| Price-to-Tangible-Book | 4.25 | |||||
| EV-to-EBIT | -4.17 | |||||
| EV-to-Forward-EBIT | -2.98 | |||||
| EV-to-EBITDA | -4.18 | |||||
| EV-to-Forward-EBITDA | -3.47 | |||||
| EV-to-Revenue | 8295.96 | |||||
| EV-to-Forward-Revenue | 41432.01 | |||||
| EV-to-FCF | -5.52 | |||||
| Price-to-Net-Current-Asset-Value | 4.32 | |||||
| Price-to-Net-Cash | 4.55 | |||||
| Earnings Yield (Greenblatt) % | -23.98 | |||||
| FCF Yield % | -13.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Altimmune Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.049 | ||
| EPS (TTM) (€) | -1.44 | ||
| Beta | 0.89 | ||
| Volatility % | 281.79 | ||
| 14-Day RSI | 43.18 | ||
| 14-Day ATR (€) | 0.371014 | ||
| 20-Day SMA (€) | 8.09495 | ||
| 12-1 Month Momentum % | 9.35 | ||
| 52-Week Range (€) | 4.9945 - 13.695 | ||
| Shares Outstanding (Mil) | 71.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Altimmune Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Altimmune Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Altimmune Inc Frequently Asked Questions
What is Altimmune Inc(STU:3G0)'s stock price today?
The current price of STU:3G0 is €7.74. The 52 week high of STU:3G0 is €13.70 and 52 week low is €4.99.
When is next earnings date of Altimmune Inc(STU:3G0)?
The next earnings date of Altimmune Inc(STU:3G0) is 2025-03-27 Est..
Does Altimmune Inc(STU:3G0) pay dividends? If so, how much?
Altimmune Inc(STU:3G0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers